300750 Contemporary Amperex Technology (A)

DGAP-News: Asterion to Hold 2019 Annual General Meeting and Corporate Presentations

DGAP-News: Asterion Cannabis Inc. / Key word(s): Miscellaneous
Asterion to Hold 2019 Annual General Meeting and Corporate Presentations

23.05.2019 / 21:19
The issuer is solely responsible for the content of this announcement.


Vancouver, British Columbia--(Newsfile Corp. - May 23, 2019) - Asterion Cannabis Inc. (P.ASTR) ("Asterion" or the "Company") announces that the Company's 2019 Annual General Meeting of Shareholders will be held at the Fairmont Vancouver Hotel in the Saturna Room, 900 West Georgia Street, Vancouver, BC, Canada on Thursday, June 20, 2019 at 12:00 p.m.

Asterion is also pleased to announce that it will be hosting two corporate events involving presentations from Asterion's senior management, details of which are set out below. Presenters at the events are expected to include Mr. Stephen Van Deventer, Chairman and CEO, Mr. Paget Hargreaves, President and Director, Mr. Hamish Sutherland, Chief Operating Officer and Mr. Stewart McGlashan, Director of Project Development.

Due to limited space, please pre-register for the events to secure your spot.

Toronto Corporate Presentation Event Details
Date: Tuesday, June 18th, 2019
Time: 1:00 pm - 4:00 pm
Presentation: 1:30 pm - 2:30 pm
Location: Fairmont Royal York
Tudor Room 7 and 8
100 Front St W, Toronto, Ontario

MC: Stephen Van Deventer

Toronto - Confirm your attendance, register by clicking here:

Vancouver Corporate Presentation Event Details
Date: Thursday, June 20th, 2019
Time 1:00 pm - 4:00 pm
Presentation: 1:30 - 2:30
Location: Fairmont Vancouver Hotel
Saturna Room
900 West Georgia Street, Vancouver, British Columbia
MC: Stephen Van Deventer

Vancouver - Confirm your attendance, register by clicking here:

About Asterion

Asterion is a Canadian medicinal cannabis company with operations in Australia, specializing in medical cannabis and is focused on becoming an industry leader in next-generation cannabis products. The Company is focused on the future of precision agriculture and aims to produce the highest quality of genetically uniform cannabis strains, at an affordable price.

The Company is led by a team of highly experienced executives with over 120 years of combined experience in medical cannabis, renewable energy, capital markets, and other highly relevant sectors across North America, Oceania, Europe, Africa and Asia.

On Behalf of the Board of Directors

"Stephen Van Deventer"
Chairman & Chief Executive Officer

For further information, please contact:

Deanna Kress

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. Other than statements of historical fact, all statements included in this news release, including, without limitation, statements regarding the Company's anticipated business plans and prospects of success in executing its plans, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Various risks and uncertainties could cause actual results to differ materially from Asterion's expectations. Other factors such as general economic, market or business conditions, future prices of cannabis, changes in the financial markets and in the demand and market price for cannabis, or changes in laws, regulations and policies affecting the biotechnology or cannabis industry, and delays in obtaining governmental and regulatory approvals, may also adversely affect the future results or performance of the Company. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

45012_6089296c24315b3c_logo.jpg

To view the source version of this press release, please visit

newsinfo.php?i=45012&f=169

Click on, or paste the following link into your web browser,to view the associated documents /release/45012


23.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Asterion Cannabis Inc.
Canada
EQS News ID: 815447

 
End of News DGAP News Service

815447  23.05.2019 

fncls.ssp?fn=show_t_gif&application_id=815447&application_name=news&site_id=research_pool
EN
23/05/2019

Underlying

300750Contemporary Amperex Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Contemporary Amperex Technology (A)

 PRESS RELEASE

DGAP-News: ADL Bionatur Solutions Wins New Fermentation Client With Co...

DGAP-News: ADL Bionatur Solutions / Key word(s): Agreement ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million 02.12.2019 / 09:06 The issuer is solely responsible for the content of this announcement. ADL BIONATUR SOLUTIONS WINS NEW FERMENTATION CLIENT WITH CONTRACT REVENUES OF EUR 20 MILLION The agreement with a leading Swiss biotech company includes technology transfer, upscaling and industrial-scale production of high value-added innovative ingredients for the cosmetics and nutrition industry ADL to apply its expertise in a...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: Dozens Savings Plc 5.00% Secured Bonds due 2 December 2020 ISIN: GB00BL1GTZ11  Symbol: DS04 EMS: 1 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   W...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: SAPO PLC Ordinary Shares of GBP 0.01 ISIN: GB00B16GQJ90 Symbol: SAPO EMS: 5000 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   Website: ...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publishes open letter to Dr. Martin Haefner...

EQS Group-News: Dynamics Group AG / Key word(s): Statement/Corporate Action LIWET HOLDING AG publishes open letter to Dr. Martin Haefner in various Swiss Sunday newspapers 01.12.2019 / 05:59 Open letter to Dr. Martin Haefner Dear Mr Haefner We share your concern about the future of Schmolz+Bickenbach (S+B). The company urgently needs money, everyone - including Liwet - agrees. However, there is still time to find a constructive solution for S+B that is in the interest of all, not only one particular shareholder. Liwet is ready to rescue the company and the 10,000 jobs. Liw...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haef...

EQS Group-News: Dynamics Group AG / Schlagwort(e): Stellungnahme/Kapitalmaßnahme LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haefner in verschiedenen Schweizer Sonntagszeitungen 01.12.2019 / 05:59 Offener Brief an Dr. Martin Haefner Sehr geehrter Herr Haefner Wir teilen Ihre Sorge um die Zukunft von Schmolz+Bickenbach (S+B). Die Firma braucht dringend Geld; damit sind alle - auch Liwet - einverstanden. Noch bleibt Zeit, um eine konstruktive Lösung für S+B zu finden, die im Interesse aller Aktionäre ist, nicht nur eines einzigen. Liwet steht bereit, die Fir...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch